Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer
2025-10-01
|
| Reeks: | Discover Oncology |
| Onderwerpen: | |
| Online toegang: | https://doi.org/10.1007/s12672-025-03569-x |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|